84 related articles for article (PubMed ID: 22890637)
1. Global cerebral atrophy after subarachnoid hemorrhage: a possible marker of acute brain injury and assessment of its impact on outcome.
Tam AK; Ilodigwe D; Li Z; Schweizer TA; Macdonald RL
Acta Neurochir Suppl; 2013; 115():17-21. PubMed ID: 22890637
[TBL] [Abstract][Full Text] [Related]
2. Impact of global cerebral atrophy on clinical outcome after subarachnoid hemorrhage.
Tam AK; Kapadia A; Ilodigwe D; Li Z; Schweizer TA; Macdonald RL
J Neurosurg; 2013 Jul; 119(1):198-206. PubMed ID: 23662822
[TBL] [Abstract][Full Text] [Related]
3. Clazosentan: prevention of cerebral vasospasm and the potential to overcome infarction.
Beck J; Raabe A
Acta Neurochir Suppl; 2011; 110(Pt 2):147-50. PubMed ID: 21125461
[TBL] [Abstract][Full Text] [Related]
4. Thick and Diffuse Subarachnoid Blood as a Treatment Effect Modifier of Clazosentan After Subarachnoid Hemorrhage.
Mayer SA; Aldrich EF; Bruder N; Hmissi A; Macdonald RL; Viarasilpa T; Marr A; Roux S; Higashida RT
Stroke; 2019 Oct; 50(10):2738-2744. PubMed ID: 31394993
[TBL] [Abstract][Full Text] [Related]
5. Effects of the selective endothelin A (ET(A)) receptor antagonist Clazosentan on cerebral perfusion and cerebral oxygenation following severe subarachnoid hemorrhage - preliminary results from a randomized clinical series.
Barth M; Capelle HH; Münch E; Thomé C; Fiedler F; Schmiedek P; Vajkoczy P
Acta Neurochir (Wien); 2007; 149(9):911-8; discussion 918. PubMed ID: 17700991
[TBL] [Abstract][Full Text] [Related]
6. Randomised trial of clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid hemorrhage undergoing surgical clipping (CONSCIOUS-2).
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
Acta Neurochir Suppl; 2013; 115():27-31. PubMed ID: 22890639
[TBL] [Abstract][Full Text] [Related]
7. Method of aneurysm treatment does not affect clot clearance after aneurysmal subarachnoid hemorrhage.
Ibrahim GM; Vachhrajani S; Ilodigwe D; Kassell NF; Mayer SA; Ruefenacht D; Schmiedek P; Weidauer S; Pasqualin A; Macdonald RL
Neurosurgery; 2012 Jan; 70(1):102-9; discussion 109. PubMed ID: 21788917
[TBL] [Abstract][Full Text] [Related]
8. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1): randomized, double-blind, placebo-controlled phase 2 dose-finding trial.
Macdonald RL; Kassell NF; Mayer S; Ruefenacht D; Schmiedek P; Weidauer S; Frey A; Roux S; Pasqualin A;
Stroke; 2008 Nov; 39(11):3015-21. PubMed ID: 18688013
[TBL] [Abstract][Full Text] [Related]
9. Different effects of clazosentan on consequences of subarachnoid hemorrhage in rats.
Chen G; Tariq A; Ai J; Sabri M; Jeon HJ; Tang EJ; Lakovic K; Wan H; Macdonald RL
Brain Res; 2011 May; 1392():132-9. PubMed ID: 21466789
[TBL] [Abstract][Full Text] [Related]
10. Dissociation of vasospasm-related morbidity and outcomes in patients with aneurysmal subarachnoid hemorrhage treated with clazosentan: a meta-analysis of randomized controlled trials.
Shen J; Pan JW; Fan ZX; Xiong XX; Zhan RY
J Neurosurg; 2013 Jul; 119(1):180-9. PubMed ID: 23641823
[TBL] [Abstract][Full Text] [Related]
11. Patient age and vasospasm after subarachnoid hemorrhage.
Ryttlefors M; Enblad P; Ronne-Engström E; Persson L; Ilodigwe D; Macdonald RL
Neurosurgery; 2010 Oct; 67(4):911-7. PubMed ID: 20881555
[TBL] [Abstract][Full Text] [Related]
12. Patient phenotypes associated with outcomes after aneurysmal subarachnoid hemorrhage: a principal component analysis.
Ibrahim GM; Morgan BR; Macdonald RL
Stroke; 2014 Mar; 45(3):670-6. PubMed ID: 24425125
[TBL] [Abstract][Full Text] [Related]
13. Impact of systemic inflammatory response syndrome on vasospasm, cerebral infarction, and outcome after subarachnoid hemorrhage: exploratory analysis of CONSCIOUS-1 database.
Tam AK; Ilodigwe D; Mocco J; Mayer S; Kassell N; Ruefenacht D; Schmiedek P; Weidauer S; Pasqualin A; Macdonald RL
Neurocrit Care; 2010 Oct; 13(2):182-9. PubMed ID: 20593247
[TBL] [Abstract][Full Text] [Related]
14. Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, double-blind, placebo-controlled phase 3 trial (CONSCIOUS-2).
Macdonald RL; Higashida RT; Keller E; Mayer SA; Molyneux A; Raabe A; Vajkoczy P; Wanke I; Bach D; Frey A; Marr A; Roux S; Kassell N
Lancet Neurol; 2011 Jul; 10(7):618-25. PubMed ID: 21640651
[TBL] [Abstract][Full Text] [Related]
15. Clazosentan for Aneurysmal Subarachnoid Hemorrhage: An Updated Meta-Analysis with Trial Sequential Analysis.
Cho SS; Kim SE; Kim HC; Kim WJ; Jeon JP
World Neurosurg; 2019 Mar; 123():418-424.e3. PubMed ID: 30508597
[TBL] [Abstract][Full Text] [Related]
16. Classification of cerebral infarction after subarachnoid hemorrhage impacts outcome.
Naidech AM; Bendok BR; Bassin SL; Bernstein RA; Batjer HH; Bleck TP
Neurosurgery; 2009 Jun; 64(6):1052-7; discussion 1057-8. PubMed ID: 19487883
[TBL] [Abstract][Full Text] [Related]
17. The effect of endothelin receptor antagonists on vasospasm following aneurysmal subarachnoid hemorrhage.
Komotar RJ; Starke RM; Connolly ES
Neurosurgery; 2011 Dec; 69(6):N13-4. PubMed ID: 22067343
[No Abstract] [Full Text] [Related]
18. Interobserver variability in the interpretation of computed tomography following aneurysmal subarachnoid hemorrhage.
Ibrahim GM; Weidauer S; Macdonald RL
J Neurosurg; 2011 Dec; 115(6):1191-6. PubMed ID: 21819195
[TBL] [Abstract][Full Text] [Related]
19. Dissociation of vasospasm and secondary effects of experimental subarachnoid hemorrhage by clazosentan.
Sabri M; Ai J; Macdonald RL
Stroke; 2011 May; 42(5):1454-60. PubMed ID: 21454820
[TBL] [Abstract][Full Text] [Related]
20. Microthrombosis after experimental subarachnoid hemorrhage: time course and effect of red blood cell-bound thrombin-activated pro-urokinase and clazosentan.
Pisapia JM; Xu X; Kelly J; Yeung J; Carrion G; Tong H; Meghan S; El-Falaky OM; Grady MS; Smith DH; Zaitsev S; Muzykantov VR; Stiefel MF; Stein SC
Exp Neurol; 2012 Jan; 233(1):357-63. PubMed ID: 22079156
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
